LON:INDV Indivior (INDV) Share Price, News & Analysis → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free INDV Stock Alerts GBX 1,337 -15.00 (-1.11%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range 1,337▼ 1,37650-Day Range 1,337▼ 1,71752-Week Range 1,125▼ 1,938Volume212,528 shsAverage Volume396,706 shsMarket Capitalization£1.81 billionP/E Ratio44,566.67Dividend Yield1.12%Price TargetGBX 2,515 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Indivior alerts: Email Address Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Indivior Stock (LON:INDV)Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More INDV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDV Stock News HeadlinesMay 11, 2024 | americanbankingnews.comIndivior (LON:INDV) Stock Passes Below Two Hundred Day Moving Average of $1,431.43May 1, 2024 | lse.co.ukLondon open: FTSE edges higher ahead of Fed; Nationwide data in focusApril 26, 2024 | finance.yahoo.comWhy Indivior PLC (LON:INDV) Looks Like A Quality CompanyApril 14, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - INDVMarch 12, 2024 | msn.comThis Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not NaloxoneFebruary 29, 2024 | markets.businessinsider.comIndivior Says Final Court Approval Concludes Antitrust Multidistrict LitigationFebruary 24, 2024 | reuters.comEurope's STOXX 600 at all-time high as Nvidia boosts global tech sharesFebruary 22, 2024 | msn.comIndivior weighs moving primary listing to U.S.February 10, 2024 | finance.yahoo.comIndivior PLC (LON:INDV) Shares Could Be 44% Below Their Intrinsic Value EstimateJanuary 18, 2024 | markets.businessinsider.comAdial Announces Appointment of Tony Goodman as Chief Operating OfficerNovember 20, 2023 | finance.yahoo.comGreat week for Indivior PLC (LON:INDV) institutional investors after losing 22% over the previous yearNovember 9, 2023 | msn.comIndivior PLC (INDV) Tops Q3 Earnings and Revenue EstimatesOctober 2, 2023 | finance.yahoo.comIndivior PLC (INDV): Unveiling Its Market ValueSeptember 26, 2023 | finance.yahoo.comIndivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in CanadaSeptember 7, 2023 | finance.yahoo.comIndivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market ValueJune 12, 2023 | finance.yahoo.comThe 7.5% return this week takes Indivior's (LON:INDV) shareholders three-year gains to 372%June 12, 2023 | finance.yahoo.comIndivior to Commence Trading on NasdaqJune 7, 2023 | msn.comJefferies Reiterates Indivior (LSE:INDV) Buy RecommendationJune 5, 2023 | reuters.comIndivior opioid settlement makes purer M&A caseJune 3, 2023 | msn.comUS drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claimsJune 2, 2023 | finanznachrichten.deIndivior PLC: Indivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation ClaimsMay 25, 2023 | uk.finance.yahoo.comINDV.L - Indivior PLCMay 25, 2023 | finance.yahoo.comIndivior To Participate In Upcoming Investor ConferencesMay 23, 2023 | finance.yahoo.comIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12thMay 22, 2023 | markets.businessinsider.comFDA Approves Opiant's Nasal Spray 'Opvee' To Reverse Opioid OverdoseSee More Headlines Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:INDV CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,515 High Stock Price TargetGBX 2,700 Low Stock Price TargetGBX 2,330 Potential Upside/Downside+88.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.03 Trailing P/E Ratio44,566.67 Forward P/E Ratio1,261.32 P/E Growth-5.57Net Income£5 million Net Margins0.44% Pretax MarginN/A Return on Equity12.20% Return on Assets9.94% Debt Debt-to-Equity Ratio2,790.00 Current Ratio0.93 Quick Ratio1.52 Sales & Book Value Annual Sales£1.12 billion Price / Sales1.62 Cash FlowGBX 498.86 per share Price / Cash Flow2.68 Book ValueGBX 7 per share Price / Book191.00Miscellaneous Outstanding Shares135,340,000Free FloatN/AMarket Cap£1.81 billion OptionableNot Optionable Beta0.02 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Mark CrossleyCEO & Executive DirectorMr. Ryan PreblickCFO & Executive DirectorDr. Christian HeidbrederChief Scientific OfficerMr. Jason ThompsonVice President of Investor RelationsMs. Cynthia CetaniChief Integrity & Compliance OfficerMr. Jeffrey W. Burris (Age 52)Chief Legal Officer Mr. Jon FogleChief Human Resources OfficerMr. Richard SimkinChief Commercial OfficerMr. Hillel WestChief Manufacturing & Supply OfficerMr. Vishal KaliaSVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy OfficerMore ExecutivesKey CompetitorsHUTCHMEDLON:HCMHikma PharmaceuticalsLON:HIKClinigen GroupLON:CLINEMIS GroupLON:EMISGenusLON:GNSView All CompetitorsInsidersMark CrossleySold 10,549 sharesTotal: £17.06 M ($1,617.00/share)Mark CrossleySold 15,444 sharesTotal: £25.39 M ($1,644.00/share)Graham HetheringtonBought 1,743 shares on 12/20/2023Total: £2.07 M ($1,189.00/share)Graham HetheringtonBought 2,650 shares on 11/20/2023Total: £3.58 M ($1,350.00/share)View All Insider Transactions INDV Stock Analysis - Frequently Asked Questions Should I buy or sell Indivior stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDV shares. View INDV analyst ratings or view top-rated stocks. What is Indivior's stock price target for 2024? 1 brokers have issued twelve-month price objectives for Indivior's shares. Their INDV share price targets range from GBX 2,330 to GBX 2,700. On average, they predict the company's share price to reach GBX 2,515 in the next year. This suggests a possible upside of 88.1% from the stock's current price. View analysts price targets for INDV or view top-rated stocks among Wall Street analysts. How have INDV shares performed in 2024? Indivior's stock was trading at GBX 1,185 at the start of the year. Since then, INDV stock has increased by 12.8% and is now trading at GBX 1,337. View the best growth stocks for 2024 here. Is Indivior a good dividend stock? Indivior (LON:INDV) pays an annual dividend of GBX 15 per share and currently has a dividend yield of 4.48%. INDV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 50,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:INDV) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.